DE69118889D1 - R(+)-terazosin - Google Patents

R(+)-terazosin

Info

Publication number
DE69118889D1
DE69118889D1 DE69118889T DE69118889T DE69118889D1 DE 69118889 D1 DE69118889 D1 DE 69118889D1 DE 69118889 T DE69118889 T DE 69118889T DE 69118889 T DE69118889 T DE 69118889T DE 69118889 D1 DE69118889 D1 DE 69118889D1
Authority
DE
Germany
Prior art keywords
terazosin
hydratet
dimethox
furanyl
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69118889T
Other languages
English (en)
Other versions
DE69118889T2 (de
Inventor
John Kyncl
Bruce Horrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69118889D1 publication Critical patent/DE69118889D1/de
Application granted granted Critical
Publication of DE69118889T2 publication Critical patent/DE69118889T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69118889T 1990-06-29 1991-06-26 R(+)-terazosin Expired - Fee Related DE69118889T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/546,349 US5212176A (en) 1990-06-29 1990-06-29 R(+)-terazosin
PCT/US1991/004562 WO1992000073A1 (en) 1990-06-29 1991-06-26 R(+)-terazosin
CA002086974A CA2086974C (en) 1990-06-29 1993-01-08 R(+)-terazosin

Publications (2)

Publication Number Publication Date
DE69118889D1 true DE69118889D1 (en) 1996-05-23
DE69118889T2 DE69118889T2 (de) 1996-11-07

Family

ID=25675811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69118889T Expired - Fee Related DE69118889T2 (de) 1990-06-29 1991-06-26 R(+)-terazosin

Country Status (14)

Country Link
US (1) US5212176A (de)
EP (1) EP0536329B1 (de)
JP (1) JPH07119222B2 (de)
AT (1) ATE136779T1 (de)
AU (1) AU654148B2 (de)
CA (1) CA2086974C (de)
DE (1) DE69118889T2 (de)
DK (1) DK0536329T3 (de)
ES (1) ES2089224T3 (de)
GR (1) GR3020364T3 (de)
IE (1) IE72967B1 (de)
IL (1) IL98562A (de)
PT (1) PT98148B (de)
WO (1) WO1992000073A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
AU5546194A (en) * 1992-11-04 1994-05-24 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
AU5549494A (en) * 1992-11-04 1994-05-24 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of hypertension
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
JPH11507395A (ja) * 1995-11-15 1999-06-29 メルク エンド カンパニー インコーポレーテッド アルファ１ａ アドレナリン受容体拮抗薬
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
WO2000006565A1 (en) 1998-07-30 2000-02-10 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
WO2000025782A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
DE19856440C2 (de) * 1998-12-08 2002-04-04 Bosch Gmbh Robert Übertragungsrahmen und Funkeinheit mit Übertragungsrahmen
DE19861323B4 (de) * 1998-12-08 2006-02-16 Robert Bosch Gmbh Verfahren zur Übertragung von Kurznachrichten
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
JP2002121188A (ja) * 2000-07-18 2002-04-23 Toray Ind Inc ピペラジンアミド化合物の製造法およびピペラジンテトラヒドロフラン−２−カルボン酸アミド誘導体
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002054996A2 (en) * 2000-10-23 2002-07-18 Euro Celtique Sa Terazosin transdermal device and methods
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
CN101547696A (zh) * 2006-08-08 2009-09-30 奥斯拜客斯制药有限公司 具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
ES2390323T3 (es) 2007-05-23 2012-11-08 Allergan, Inc. Compuestos terapéuticos de ((fenil)imidazolil)metilquinolinilo
WO2008144623A1 (en) 2007-05-23 2008-11-27 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US7829587B2 (en) 2008-01-09 2010-11-09 Allergan, Inc. Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US8809379B2 (en) 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
BRPI0906925A2 (pt) 2008-01-18 2019-09-24 Allergan Inc agentes adrenérgicos do subtipo alfa 2 seletivos e métodos de uso dos mesmos
US20090239918A1 (en) * 2008-03-24 2009-09-24 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US8420114B2 (en) 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
CA2723751A1 (en) 2008-05-05 2009-11-12 Allergan, Inc. Alpha2b and alpha2c agonists
JP5710470B2 (ja) 2008-05-16 2015-04-30 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 選択的サブタイプアルファ２アドレナリン作用薬及びこれらの使用方法
ES2495099T3 (es) 2008-12-08 2014-09-16 Allergan, Inc. Compuestos de N-(1-fenil-2-ariletil)-4,5-dihidro-3H-pirrol-2-amina como moduladores selectivos de subtipo de los adrenoceptores alfa2B o alfa2B y alfa2C
CA2751651A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
AU2010276648A1 (en) 2009-07-30 2012-02-23 Allergan, Inc. Selective alpha 2B/2C agonists
AU2010303545B2 (en) 2009-10-06 2016-05-12 Allergan, Inc. 2H-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11224572B1 (en) * 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
JPH01216983A (ja) * 1988-02-26 1989-08-30 Hiroyuki Nohira （±）−テトラヒドロフラン−２−カルボン酸の光学分割方法

Also Published As

Publication number Publication date
PT98148A (pt) 1993-08-31
JPH07119222B2 (ja) 1995-12-20
CA2086974C (en) 2001-04-10
EP0536329A4 (en) 1993-05-19
PT98148B (pt) 1998-12-31
ATE136779T1 (de) 1996-05-15
US5212176A (en) 1993-05-18
DK0536329T3 (da) 1996-08-12
ES2089224T3 (es) 1996-10-01
IL98562A (en) 1995-12-31
AU8323191A (en) 1992-01-23
AU654148B2 (en) 1994-10-27
EP0536329A1 (de) 1993-04-14
GR3020364T3 (en) 1996-09-30
IE912086A1 (en) 1992-01-01
JPH05507280A (ja) 1993-10-21
DE69118889T2 (de) 1996-11-07
CA2086974A1 (en) 1994-07-09
EP0536329B1 (de) 1996-04-17
WO1992000073A1 (en) 1992-01-09
IE72967B1 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
DE69118889D1 (en) R(+)-terazosin
ITRM910959A1 (it) Apparecchio e procedimento per la correzione dello sfalsamento in cc per un ricevitore.
PH30928A (en) Pharmaceutical agents.
MD809B2 (en) (-)-Enantiomer cis-4-amino-1-(2-hydroxymethil-1,3-oxathiolan-5-yl)-
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
DE69003817D1 (de) Stimmprothese.
DE58900242D1 (de) Vertikalformschneidmaschine.
FI901679A0 (fi) Mikrofonarrangemang foer straenginstrument, speciellt foer elgitarr.
FR2660856B1 (fr) Prothese radio-cubitale inferieure.
DE69009544T2 (de) Beeinflussung eines Bildes.
NO914799L (no) Sprinkelbunn for madrasser o.l.
ITRM940393A0 (it) "macchina per la fabbricazione di sigarette".
DE69107987T2 (de) Zuschnittzuführvorrichtung.
FR2680968B1 (fr) Implant pour arthrorise sous-astragalienne.
FR2663535B1 (fr) Implant cotylouidien.
DE69103824T2 (de) Patientenliegetische.
NO971604L (no) Orale sabeluzolsuspensjoner
LTIP1714A (en) New pharmaceutical formulations
GB9105544D0 (en) Suction table,especially for an exposure station
IT1243851B (it) Cilindro di regolazione dell'inflessione.
ES1017933Y (es) Maquina tundidora de tejido.
SE9000288D0 (sv) New use
ITRM910206U1 (it) Cuscinetto-spessore di fermo per protesi dentarie.
ES1019796Y (es) Maquina de masajes corporales.
ES1020141Y (es) Maquina nebulizadora.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee